{
  "treatment_arm_id": "APEC1621-D",
  "name": "APEC1621-D",
  "version": "2015-08-06",
  "stratum_id": "100",
  "date_created":"2017-02-22",
  "treatment_arm_status": "OPEN",
  "assay_rules": [],
  "study_id": "APEC1621SC",
  "num_patients_assigned": null,
  "treatment_arm_drugs": [{
    "name": "Crizotinib",
    "pathway": "ALK",
    "drug_id": "113"
  }],
  "snv_indels": [],
  "gene_fusions":[],
  "non_hotspot_rules": [
    {
      "variant_type":"nhr",
      "inclusion": true,
      "func_gene": "KRAS",
      "domain_range":"400-500",
      "level_of_evidence": 3.0
    }
  ],
  "copy_number_variants": [],
  "diseases": [{
    "disease_code_type":"ICD-O",
    "disease_code": "10058354",
    "disease_name": "Bronchioloalveolar carcinoma",
    "exclusion":true
  },{
    "disease_code_type":"ICD-O",
    "disease_code": "10033701",
    "disease_name": "Papillary thyroid carcinoma",
    "exclusion":false
  }],
  "exclusion_drugs": [{
    "name": "Doxorubicin Hydrochloride",
    "drug_id": "10001",
    "drug_class": "ALK inhibitor",
    "target": "ALK"
  }]
}